Eivind Valen Egeland

6PUBLICATIONS
51CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 14, 2026
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer.

|Apr 30, 2026
Systematic interrogation of drug sensitivities in melanoma reveals potent synergistic and antagonistic drug combinations with translational potential.

|Mar 27, 2026
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.

Amanda Poissonnier, Hope S Rugo, Wesley Horton

|Nov 24, 2025
Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.

Maria Aanesland Dahle, Jan-Lukas Førde, Eivind Valen Egeland

|Oct 10, 2024
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

Eivind Valen Egeland, Kotryna Seip, Eleni Skourti

|Jan 07, 2017
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.

Eivind Valen Egeland, Kjetil Boye, Daehoon Park

Pageof 1

Frequent Collaborators

2 joint publications

Mads Haugland Haugen

2 joint publications

Maria Aanesland Dahle

2 joint publications

Lina Prasmickaite

2 joint publications

Gunhild M Mælandsmo